Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides

Proteins: Structure, Function and Genetics

Volumn 36, Issue 2, 1999, Pages 217-227

  Nuttall, Stewart D ^a   Rousch, Mat J M ^b   Irving, Robert A ^a   Hufton, Simon E ^b   Hoogenboom, Hennie R ^b   Hudson, Peter J ^a  

^a CSIRO   (Australia)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bacteriophage; CTLA 4; Display; Peptide; Receptor; Somatostatin

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; PEPTIDE LIBRARY; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BACTERIOPHAGE; BINDING SITE; CHO CELL; ESCHERICHIA COLI; GENE MUTATION; GLYCOSYLATION; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; BACTERIOPHAGES; BINDING, COMPETITIVE; CAPSID; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; GLYCOSYLATION; HUMANS; IMMUNOCONJUGATES; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN FOLDING; RECEPTORS, SOMATOSTATIN; RECOMBINANT FUSION PROTEINS; SOLUBILITY; SOMATOSTATIN;

EID: 0033181011     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0134(19990801)36:2<217::AID-PROT7>3.0.CO;2-X     Document Type: Article

References (50)

1. Ladner RC. Constrained peptides as binding entities. Trends Biotechnology 1995;13:426-30.
2. Vita C. Engineering novel proteins by transfer of active sites to natural scaffolds. Curr Opin Biotechnol 1997;8:429-434.
3. Nygren P-Å, Uhlén M. Scaffolds for engineering novel binding sites in proteins. Curr Opin Struct Biol 1997;7:463-469.
4. Hoogenboom HR, De Bruine AP, Hufton SE, Hoet RM, Arends J-W, Roovers RC. Antibody phage display technology and its applications. Immunotechnology 1998;4:1-20.
5. Atwell S, Ultsch M, De Vos AM, Wells JA. Structural plasticity in a remodeled protein-protein interface. Science 1997;278:1125-1128.
6. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrikson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralising human antibody. Nature 1998;393:648-659.
7. Hudson PJ. Recombinant antibody fragments. Curr Opin Biotechnol 1998;9:395-402.
8. Sheriff S, Constantine KL. Redefining the minimal antigen-binding fragment. Nat Struct Biol 1996;3:733-736.
9. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from E. coli. Nature 1989;341:541-543.
10. Kortt AA, Guthrie RE, Hinds MG, et al. Solution properties of E. coli expressed VH domain of anti-neuraminidase antibody NC41. J Protein Chem 1995;14:167-178.
11. Davies J, Riechmann L. Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding. Immunotechnology 1996;2:169-179.
12. Dimasi N, Martin F, Volpari C, et al. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. J Virol 1997;71:7461-7469.
13. Zappacosta F, Ingallinella P, Scaloni A, et al. Surface topology of Minibody by selective chemical modifications and mass spectrometry. Protein Sci 1997;6:1901-1909.
14. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363: 446-448.
15. Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng 1994;7:1129-1135.
16. Roux KH, Greenberg AS, Greene L, et al. Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. Proc Natl Acad Sci USA 1998;95:11804-11809.
17. Desmyter A, Transue TR, Ghahroudi MA, et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme Nat Struct Biol 1996;3:803-811.
18. Lauwereys M, Ghahroudi MA, Desmyter A, et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 1998;17:3512-3520.
19. Transue TR, De Genst E, Ghahroudi MA, Wyns L, Muyledmans S. Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. Proteins 1998;32:515-522.
20. Davies J, Riechmann L. Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng 1996;9:531-537.
21. Brunet JF, Denizot F, Luciani M-F, et al. A new member of the immunoglobulin superfamily CTLA-4. Nature 1987;438:267-270.
22. Peach RJ, Bajorath J, Brady W, et al. Complementarity determining region 1 (CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1994;180:2049-2058.
23. Waterhouse P, Marengere LE, Mittrücker HW, Mak TW. CTLA-4, a negative regulator of T-lymphocyte activation. Immunol Rev 1996;153:183-207.
24. Linsley PS, Nadler SG, Bajorath J, et al. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules. J Biol Chem 1995;270:15417-15424.
25. Metzler WJ, Bajorath J, Fenderson W, et al. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nat Struct Biol 1997;4:527-531.
26. Morton PA, Fu XT, Stewart JA, et al. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). J Immunol 156:1047-1054. 1996;
27. van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997;185:393-403.
28. Linsley PS, Clark EA, Ledbetter JA. The T cell antigen CD28 mediates adhesion with B cells by interacting with the activation antigen, B7/BB1. Proc Natl Acad Sci USA 1990;87:5031-5035.
29. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397:263-266.
30. Gerstmayer B, Pessara U, Wels W. Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7-1 and B7-2 and the B7 counter-receptor CTLA-4. FEBS Lett 1997;407:63-68.
31. Schonbrunn A, Gu YZ, Brown PJ, Loose-Mitchell D. Function and regulation of somatostatin receptor subtypes. Ciba Found Symp 1995;190:204-217.
32. Reisine T. Somatostatin. Cell Mol Neurobiol 1995;15:597-614.
33. Rousch M, Lutgerink JT, Coote J, de Bruïne AD, Arends J-W, Hoogenboom HR. Somatostatin displayed on filamentous phage is a receptor-specific agonist. Br J Pharm 1998;125:5-16.
34. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 41:63-70. 1997;
35. Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology. New York: John Wiley & Sons; 1989.
36. Coia G, Hudson PJ, Lilley GG. Construction of recombinant extended single-chain antibody peptide conjugates for use in the diagnosis of HIV-1 and HIV-2. J. Immunol Meth 192:13-23. 1996;
37. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature 352:624-628. 1991;
38. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991;222:581-597.
39. Galanis M, Irving RA, Hudson PJ. Bacteriophage library construction and selection of recombinant antibodies. Current Protocols in Immunology 17.1.1-17.1.45. New York: John Wiley & Sons; 1997.
40. Minsky A, Summers RG, Knowles JR. Secretion of beta-lactamase into the periplasm of Escherichia coli: evidence for a distinct release step associated with a conformational change. Proc Natl Acad Sci USA 1986;83:4180-4184.
41. Brizzard BL, Chubet RG, Vizard DL. Immunoaffinity purification of FLAG epitope-tagged bacterial alkaline phosphatase using a novel monoclonal antibody and peptide elution. Biotechniques 1994;16:730-735.
42. Rees S, Coote J, Stable J, Goodson S, Harris S, Lee MG. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 1996;20:102-110.
43. Truneh A, Reddy M, Ryan P, et al. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis. Mol Immunol 1996;33:321-334.
44. Elbein AD. The tunicamycins - useful tools for studies on glycoproteins. Trends Biochem Sci 1981;6:219-221.
45. Bodian DL, Jones EY, Harlos K, Stuart DI, Davis SJ. Crystal structure of the extracellular region of the human cell adhesion molecule CD2 at 2.5 A resolution. Structure 1994;2:755-766.
46. Davis SJ, van der Merwe PA. The structure and ligand interactions of CD2: implications for T-cell function. Immunol Today 1996;17:177-187.
47. Lowman HB. Bacteriophage display and discovery of peptide leads for drug development. Ann Rev Biophys Biomol Struct 1997;26:401-424.
48. Petrenko VA, Smith GP, Gong X, Quinn T. A library of organic landscapes on filamentous phage. Protein Eng 1996;9:797-801.
49. Hocart SJ, Reddy V, Murphy WA, Coy DH. Three-dimensional quantitative structure-activity relationships of somatostatin analogues. 1. Comparative molecular field analysis of growth hormone release-inhibiting potencies. J Med Chem 1995;38:1974-1989.
50. Melacini G, Zhu Q, Goodman M. Multiconformational NMR analysis of sandostatin (octreotide): equilibrium between beta-sheet and partially helical structures. Biochemistry 1997;36:1233-1241.